Skip to main content
Fig. 2 | BMC Gastroenterology

Fig. 2

From: Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma

Fig. 2

Kaplan–Meier curves demonstrating survival based on age, BCLC stage, tumor burden, and tumor response. a The median overall survival is significantly better in patients aged above 65 years than in those aged below 65 years (30.5 vs. 19.1 months; p = 0.017). b The median overall survival was significantly better in patients with BCLC stage B than in those with BCLC stage C (31.2 vs. 21.2 months; p = 0.018). c The median overall survival was significantly better in patients with tumor burden under 25% than in those with tumor burden 25–50% and above 50% (33.1, vs. 15.9 and 9.7 months; p < 0.001). d The median overall survival was significantly better in patients with objective tumor response (CR/PR) than in those with SD/PD (40.1 vs. 16.3 months; p < 0.001)

Back to article page